Spasticity.
D003620:Dantrolene / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D018377:Neurotransmitter Agents / Q000009:adverse effects / Q000627:therapeutic use; D010276:Parasympatholytics / Q000009:adverse effects / Q000627:therapeutic use; D013035:Spasm / Q000150:complications / Q000209:etiology / Q000503:physiopathology / Q000628:therapy
D018377:Neurotransmitter Agents; D010276:Parasympatholytics; D003620:Dantrolene